Newborn Acquisition Corp

Newborn Acquisition Corp (Nasdaq: NBAC), sponsored by Newborn Capital Group, was a healthcare-focused special purpose acquisition company that completed its initial public offering in 2020. The blank-check company targeted opportunities in the biopharmaceutical and life sciences sectors. In early 2021, NBAC announced and pursued a business combination with Nuvation Bio, a clinical-stage oncology company developing differentiated cancer therapies. The DEFA14A filed March 8, 2021 represents supplemental proxy materials distributed to shareholders in connection with the proposed merger vote. The transaction closed in 2021, with the combined company subsequently trading on the New York Stock Exchange under the ticker NUVB. For complete filing history, sponsor disclosures, and deal metrics on NBAC and thousands of other SPACs, sign up for full data access at SpacDesk.